Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Bausch + Lomb recently held its third-quarter 2025 financial results presentation, highlighting several aspects of its performance and strategic focus.</li><li>The company demonstrated notable growth across its various segments, driven by innovative product offerings and rigorous execution.</li><li>Revenue for the quarter reached $1.281 billion, marking a 6% year-over-year increase.</li></ul>

Bausch + Lomb recently held its third-quarter 2025 financial results presentation, highlighting several aspects of its performance and strategic focus.The company demonstrated notable growth across its various segments, driven by innovative product offerings and rigorous execution.Revenue for the quarter reached $1.281 billion, marking a 6% year-over-year increase.

Bausch + Lomb Corporation’s Growth Surge: Can New Contact Lens Tech Grab A Larger Chunk Of The Market?

<ul><li>Bausch + Lomb's second quarter 2025 results reflect a mix of solid performance and ongoing strategic challenges.</li><li>The company's revenue grew by 3% year-over-year, reaching $1.278 billion, spurred by robust growth in their contact lenses and consumer segments, despite facing headwinds such as the enVista intraocular lens recall and challenges in their U.S. generics business.</li><li>Positives in this performance include constant currency revenue growth of 3%, which would have been significantly higher at 6% if the enVista recall had been excluded.</li></ul>

Bausch + Lomb's second quarter 2025 results reflect a mix of solid performance and ongoing strategic challenges.The company's revenue grew by 3% year-over-year, reaching $1.278 billion, spurred by robust growth in their contact lenses and consumer segments, despite facing headwinds such as the enVista intraocular lens recall and challenges in their U.S. generics business.Positives in this performance include constant currency revenue growth of 3%, which would have been significantly higher at 6% if the enVista recall had been excluded.

Bausch & Lomb: How Their Xiidra + Miebo Combo Could Redefine Dry Eye Treatment!

<ul><li>Bausch + Lomb's second quarter 2025 financial results depict a mixed scenario, characterized by both advancements and challenges within the company.</li><li>During this quarter, Bausch + Lomb reported a revenue of $1.278 billion, which represents a year-over-year growth of 3% on a constant currency basis.</li><li>This growth has been fueled primarily by advancements in its consumer, contact lenses, and promoted pharmaceutical brands.</li></ul>

Bausch + Lomb's second quarter 2025 financial results depict a mixed scenario, characterized by both advancements and challenges within the company.During this quarter, Bausch + Lomb reported a revenue of $1.278 billion, which represents a year-over-year growth of 3% on a constant currency basis.This growth has been fueled primarily by advancements in its consumer, contact lenses, and promoted pharmaceutical brands.

Bausch & Lomb: Dominating The Contact Lens Market with Cutting-Edge Innovations & Direct-to-Consumer Surge!

<ul><li>Bausch + Lomb, a prominent player in the eye health sector, reported its first-quarter results for 2025, showcasing a mixed financial and operational performance.</li><li>Revenue at the company rose, reflecting a 5% constant currency growth across its reporting segments.</li><li>The company's Vision Care and Surgical segments performed particularly well, with 5% and 11% growth, respectively.</li></ul>

Bausch + Lomb, a prominent player in the eye health sector, reported its first-quarter results for 2025, showcasing a mixed financial and operational performance.Revenue at the company rose, reflecting a 5% constant currency growth across its reporting segments.The company's Vision Care and Surgical segments performed particularly well, with 5% and 11% growth, respectively.

Bausch & Lomb Corporation: These Are The 4 Biggest Challenges In Its Path In 2025!

<ul><li>Bausch + Lomb delivered a robust financial performance in the fourth quarter of 2024, marking its fifth consecutive quarter of double-digit constant currency revenue growth.</li><li>The company achieved a 17% growth in constant currency revenue for the entire year.</li><li>This trajectory is attributed to the continuous introduction of new products and substantial enhancements in manufacturing processes, notably through the deployment of AI technologies.</li></ul>

Bausch + Lomb delivered a robust financial performance in the fourth quarter of 2024, marking its fifth consecutive quarter of double-digit constant currency revenue growth.The company achieved a 17% growth in constant currency revenue for the entire year.This trajectory is attributed to the continuous introduction of new products and substantial enhancements in manufacturing processes, notably through the deployment of AI technologies.

Bausch + Lomb: Innovative Product Launches in the Surgical Business Can Truly Shape Their Future!

United States

Bausch + Lomb is a leading supplier of contact lenses and eyecare products

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Bausch + Lomb (BLCO US)

Bausch + Lomb Corporation’s Growth Surge: Can New Contact Lens Tech Grab A Larger Chunk Of The Market?

Bausch + Lomb recently held its third-quarter 2025 financial results presentation, highlighting several aspects of its performance and strategic...

Baptista Research

Bausch & Lomb: How Their Xiidra + Miebo Combo Could Redefine Dry Eye Treatment!

Bausch + Lomb's second quarter 2025 results reflect a mix of solid performance and ongoing strategic challenges. The company's revenue grew by 3%...

Baptista Research

Bausch & Lomb: Dominating The Contact Lens Market with Cutting-Edge Innovations & Direct-to-Consumer Surge!

Bausch + Lomb's second quarter 2025 financial results depict a mixed scenario, characterized by both advancements and challenges within the...

Baptista Research

Bausch & Lomb Corporation: These Are The 4 Biggest Challenges In Its Path In 2025!

Bausch + Lomb, a prominent player in the eye health sector, reported its first-quarter results for 2025, showcasing a mixed financial and...

Baptista Research

Bausch + Lomb: Innovative Product Launches in the Surgical Business Can Truly Shape Their Future!

Bausch + Lomb delivered a robust financial performance in the fourth quarter of 2024, marking its fifth consecutive quarter of double-digit...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)